First Participant Dosed in Tisento Therapeutics’ Global Phase 2b PRIZM Study Evaluating Zagociguat for the Treatment of MELAS
January 27, 2025 07:00 ET
|
Tisento Therapeutics Inc
The first patient has been dosed in Tisento's global Phase 2b PRIZM study investigating zagociguat in MELAS.
Tisento Therapeutics Initiates Interview Study with Individuals with MELAS to Elucidate the Symptoms and Impact of Disease and Inform the Zagociguat Clinical Development Program
October 25, 2023 08:00 ET
|
Tisento Therapeutics Inc
Tisento Therapeutics Initiates Interview Study with Individuals with MELAS to Elucidate the Symptoms and Impact of Disease and Inform the Zagociguat Clinic